Welcome to LookChem.com Sign In|Join Free

CAS

  • or
DIMETHYL CIS-1,2,3,6-TETRAHYDROPHTHALATE is an organic compound that has been reported to undergo epoxidation and desymmetrization reactions. It is a derivative of phthalic acid and is characterized by its unique chemical structure and properties.

4841-84-3

Post Buying Request

4841-84-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

4841-84-3 Usage

Uses

Used in Chemical Synthesis:
DIMETHYL CIS-1,2,3,6-TETRAHYDROPHTHALATE is used as a chemical intermediate for the synthesis of various compounds. Its unique structure allows it to be a valuable building block in the creation of new molecules with potential applications in various industries.
Used in Pharmaceutical Industry:
DIMETHYL CIS-1,2,3,6-TETRAHYDROPHTHALATE is used as a key component in the development of new drugs. Its chemical properties make it suitable for use in the synthesis of pharmaceutical compounds, potentially leading to the discovery of novel treatments for various medical conditions.
Used in Polymer Industry:
DIMETHYL CIS-1,2,3,6-TETRAHYDROPHTHALATE can be used as a monomer in the production of polymers. Its unique structure may contribute to the development of new polymer materials with specific properties, such as improved strength, flexibility, or thermal stability.
Used in Research and Development:
DIMETHYL CIS-1,2,3,6-TETRAHYDROPHTHALATE is used as a research compound for studying its chemical properties and potential applications. Its epoxidation and desymmetrization reactions provide valuable insights into the behavior of similar compounds and may lead to the development of new synthetic methods and applications.

Check Digit Verification of cas no

The CAS Registry Mumber 4841-84-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,8,4 and 1 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 4841-84:
(6*4)+(5*8)+(4*4)+(3*1)+(2*8)+(1*4)=103
103 % 10 = 3
So 4841-84-3 is a valid CAS Registry Number.
InChI:InChI=1/C10H14O4/c1-13-9(11)7-5-3-4-6-8(7)10(12)14-2/h3-4,7-8H,5-6H2,1-2H3/t7-,8+

4841-84-3 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (H25952)  Dimethyl cis-4-cyclohexene-1,2-dicarboxylate, 99%   

  • 4841-84-3

  • 1g

  • 218.0CNY

  • Detail
  • Alfa Aesar

  • (H25952)  Dimethyl cis-4-cyclohexene-1,2-dicarboxylate, 99%   

  • 4841-84-3

  • 10g

  • 1058.0CNY

  • Detail

4841-84-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name DiMethyl cis-4-Cyclohexene-1,2-dicarboxylate

1.2 Other means of identification

Product number -
Other names Dimethyl cis-4-Cyclohexene-1,2-dicarboxylate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:4841-84-3 SDS

4841-84-3Downstream Products

4841-84-3Relevant articles and documents

A diastereoselective P450-catalyzed epoxidation reaction: Anti versus syn reactivity This Letter is dedicated to the memory of Harry Wasserman

Ilie, Adriana,Lonsdale, Richard,Agudo, Rubén,Reetz, Manfred T.

, p. 3435 - 3437 (2015)

The achiral cyclohexene derivative dimethyl cis-1,2,3,6-tetrahydrophthalate has been subjected to oxidation catalyzed by cytochrome P450 monooxygenase P450-BM3, leading to diastereoselective epoxidation rather than oxidative hydroxylation. This reaction occurs with 94% diastereoselectivity in favor of the anti-epoxide, in contrast to m-CPBA which delivers unselectively a 70:30 mixture of anti/syn diastereomers. The experimental results are nicely explained on a molecular level by docking experiments and molecular dynamics computations.

Novel easily accessible glucosidase inhibitors: 4-hydroxy-5-alkoxy-1,2-cyclohexanedicarboxylic acids

Brazdova, Barbora,Tan, Nikmala S.,Samoshina, Nataliya M.,Samoshin, Vyacheslav V.

, p. 311 - 321 (2009)

Glycosidases are very important enzymes involved in a variety of biochemical processes with a special importance to biotechnology, food industry, and pharmacology. Novel structurally simple inhibitors derived from cyclohexane-1,2-dicarboxylic acids were s

Novel 1,2,3-triazole compounds: Synthesis, In vitro xanthine oxidase inhibitory activity, and molecular docking studies

Tan, Ayse

, (2020)

In this study, novel 1,2,3-triazole compounds containing carbasugar frameworks (5 and 6) were synthesized by the copper-catalyzed azide-alkyne cycloaddition reactions and their in vitro inhibition effects on the enzyme xanthine oxidase were investigated. All of the synthesized compounds were characterized by spectroscopic methods. According to the enzyme inhibition results, compounds 5 (IC50 = 0.586 ± 0.017 μM) and 6 (IC50 = 0.751 ± 0.021 μM) showed stronger inhibition effects than allopurinol (IC50 = 1.143 ± 0.019 μM), which is a standard drug used for inhibition of xanthine oxidase. The binding modes of the 1,2,3-triazole compounds (5 and 6) with the active site of xanthine oxidase were explained based on molecular docking studies. The molecular docking studies showed that the aromatic structure, π-π interactions and hydrophobic interactions play a major role in xanthine oxidase inhibition for compounds 5 and 6.

Diastereoselective cis to trans desymmetrization of dimethyl succinates

Michieletto, Ivan,Fabris, Fabrizio,De Lucchi, Ottorino

, p. 2505 - 2509 (1999)

Meso-succinates, readily available by Diels-Alder cycloaddition of dimethyl maleate or maleic anhydride followed by esterification, can be isomerized quantitatively from the cis to the trans isomers in the presence of lithium alkoxides. The reaction performed with enantiopure chiral lithium alkoxides yields diastereomeric trans-succinates in good yield and selectivity.

PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS

-

Page/Page column 299-300; 360-362, (2020/10/18)

This disclosure provides pharmaceutical compounds to treat medical disorders, such as complement-mediated disorders, including complement Cl -mediated disorders.

Trans-hydrogenation: Application to a concise and scalable synthesis of brefeldin a

Fuchs, Michael,Fürstner, Alois

supporting information, p. 3978 - 3982 (2015/03/30)

The important biochemical probe molecule brefeldin A (1) has served as an inspirational target in the past, but none of the many routes has actually delivered more than just a few milligrams of product, where documented. The approach described herein is clearly more efficient; it hinges upon the first implementation of ruthenium-catalyzed trans-hydrogenation in natural products total synthesis. Because this unorthodox reaction is selective for the triple bond and does not touch the transannular alkene or the lactone site of the cycloalkyne, it outperforms the classical Birch-type reduction that could not be applied at such a late stage. Other key steps en route to 1 comprise an iron-catalyzed reductive formation of a non-terminal alkyne, an asymmetric propiolate carbonyl addition mediated by a bulky amino alcohol, and a macrocyclization by ring-closing alkyne metathesis catalyzed by a molybdenum alkylidyne.

Chemoenzymatic Sequential Multistep One-Pot Reaction for the Synthesis of (1S,2R)-1-(Methoxycarbonyl)cyclohex-4-ene-2-carboxylic Acid with Recombinant Pig Liver Esterase

Süss, Philipp,Borchert, Sonja,Wardenga, Rainer,Hinze, Janine,Illner, Sabine,Von Langermann, Jan,Kragl, Udo,Bornscheuer, Uwe T.

, p. 2034 - 2038 (2016/02/26)

In this work, the development of a chemoenzymatic process for the production of (1S,2R)-1-(methoxycarbonyl)cyclohex-4-ene-2-carboxylic acid by ECS-PLE06 (recombinant pig liver esterase) is presented. Herein an optimized esterification protocol, starting f

Scale-up of a recombinant pig liver esterase-catalyzed desymmetrization of dimethyl cyclohex-4-ene-cis-1,2-dicarboxylate

Suess, Philipp,Illner, Sabine,Von Langermann, Jan,Borchert, Sonja,Bornscheuer, Uwe T.,Wardenga, Rainer,Kragl, Udo

, p. 897 - 903 (2014/08/05)

A recombinant isoenzyme of pig liver esterase was used for the highly enantioselective desymmetrization of dimethyl cyclohex-4-ene-cis-1,2- dicarboxylate. The selected recombinant esterase showed a significant advantage in enantioselectivity over the comm

Pre-organization of the core structure of E-selectin antagonists

Schwizer, Daniel,Patton, John T.,Cutting, Brian,Smiesko, Martin,Wagner, Beatrice,Kato, Ako,Weckerle, Celine,Binder, Florian P. C.,Rabbani, Said,Schwardt, Oliver,Magnani, John L.,Ernst, Beat

supporting information; experimental part, p. 1342 - 1351 (2012/04/04)

A new class of N-acetyl-dglucosamine (GlcNAc) mimics for Eselectin antagonists was designed and synthesized. The mimic consists of a cyclohexane ring substituted with alkyl substituents adjacent to the linking position of the fucose moiety. Incorporation into E-selectin antagonists led to the test compounds 8 and the 2'-benzoylated analogues 21, which exhibit affinities in the low micromolar range. By using saturation transfer difference (STD)-NMR it could be shown that the increase in affinity does not result from an additional hydrophobic contact of the alkyl substituent with the target protein E-selectin, but rather from a steric effect stabilizing the antagonist in its bioactive conformation. The loss of affinity found for antagonists 10 and 35 containing a methyl substituent in a remote position (and therefore unable to support to the stabilization of the core) further supports this hypothesis. Finally, when a GlcNAc mimetic containing two methyl substituents (52 and 53) was used, in which one methyl was positioned adjacent to the fucose linking position and the other was in a remote position, the affinity was regained.

GLYCOMIMETIC-PEPTIDOMIMETIC INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS

-

Page/Page column 59, (2012/05/20)

Compounds, compositions and methods are provided for treating cancer and inflammatory diseases, and for releasing cells such as stem cells (e.g., bone marrow progenitor cells) into circulating blood and enhancing retention of the cells in the blood. More specifically, glycomimetic-peptidomimetic compounds that inhibit both E-selectins and CXCR4 chemokine receptors are described.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 4841-84-3